Sanofi (SAN) Stock Price, Fundamentals & Analysis

What SAN does

Sanofi (SAN) is a healthcare company headquartered in Paris, France, listed on Euronext Paris. It engages in the research, development, manufacture, and marketing of therapeutic solutions, with activities spanning immunology and inflammation, rare diseases, neurology, oncology, and vaccines. Its vaccine portfolio includes pediatric vaccines against poliomyelitis, pertussis, and haemophilus influenzae type b (Hib), respiratory syncytial virus protection, hexavalent combination vaccines, and Fluzone, a flu vaccine. The company also runs a broad network of collaborations, including agreements with Exscientia for small-molecule drug discovery, ABL Bio for ABL301, Innate Pharma for a B7-H3 cell engager program, and AI-focused partnerships with Atomwise and Insilico Medicine. With roughly 74,846 employees, it is one of the large drug manufacturers listed among Euronext Paris stocks, alongside peers such as EssilorLuxottica (EL) and Eurofins Scientific (ERF).

Key numbers explained

• Price of 71.79 EUR (down -0.43% today) against a 52-week range of 70.96 – 91.15 — the stock currently trades near the lower end of its yearly range, after a -7.9% change over the last 52 weeks.
• Market capitalization of 86.01B EUR — the total market value of all shares — places Sanofi among the large-cap names on its exchange.
• Trailing P/E ratio of 22.2 means the share price equals about 22 years of past earnings; the forward P/E of 7.9 is based on expected earnings, which are anticipated to be much higher than the trailing 3.23 EUR per share.
• Dividend yield of 5.74% indicates the annual dividend as a percentage of the share price — a relatively high income component. Note the payout ratio of 128%, meaning dividends currently exceed trailing earnings.
• Revenue of 48.92B EUR grew 14.6% year over year, a strong top-line pace for the sector.
• Profit margin of 8.1% and operating margin of 21% show how much of each euro of revenue survives as profit at different stages.
• Return on equity of 5.7% and a price-to-book ratio of 1.24 suggest the market values the company at a modest premium to its accounting net worth.
• A beta of 0.28 indicates historically low sensitivity to broad market swings, and a debt-to-equity ratio of 33.9% points to moderate leverage.

What to watch

As a large drug manufacturer, Sanofi's results depend on pipeline progress, clinical trial outcomes, and the success of its collaboration programs in oncology, immunology, and neurology. Vaccine demand and public health trends can materially affect that segment. Regulatory decisions, patent expirations, and pricing policies in major markets are typical swing factors for the industry. The upcoming earnings date of Oct 30, 2026 will be a scheduled checkpoint for revenue and margin trends, and the May 5, 2026 ex-dividend date matters for income-focused holders. Sector-wide, peers such as Fosun Pharmaceutical (600196), Astellas (4503), and Alcon Inc (ALC) face similar dynamics, so comparing results across the stocks directory can provide context.